Drug Delivery Technologies Revolutionizing Cancer Therapies
PharmaVision
April 27, 2007 80 Pages - SKU: PBA2268116
|
|
“One of the biggest issues with current cancer therapies is that whilst most therapies procure quality of life they kill both healthy and tumor cells. This offers drug delivery specialists one of the greatest challenges and opportunities to increase the therapeutic index and ultimately deliver targeted therapies to cancer cells whilst minimizing off-target side effects.”
Dr Cheryl Barton.
The burden of disease cancer puts on society is huge. In 2000 it was estimated that over 10 million people were diagnosed with cancer worldwide and global incidence is expected to grow to 15 million by 2020 (source: WHO). It is the second leading cause of death in the US and results in overall costs of more than US$210 billion annually.
Whilst significant advances have been made in the treatment of many cancer subtypes, the therapies currently available often require regular visits to the hospital or clinic to receive radioactive therapy or intravenous chemotherapy which are highly toxic, may lead to drug resistance and are poorly tolerated due to limited-tumor specificity leading to many unwanted sideeffects and poor compliance.
Whilst the pharmaceutical industry continues to find innovative ways to treat cancer, drug delivery specialists have the task of making sure those treatments reach the correct site in the body in the required quantities and at the right time. The Holy Grail in delivering cancer therapies is the development of a technology platform which targets the therapy only to the tumor, leaving normal cells undamaged. In an ideal world, orally active targeted therapies would be available.
The following report summarizes some of the latest developments in cancer drug development and analyzes some of the most promising solutions which drug delivery companies are providing in order to address this unmet clinical need.
|
- 1 The cancer market and drug delivery technology opportunities
- 1.1 Introduction
- 1.2 Overview of the market
- 1.2.1 Market size
- 1.2.2 Key pharma players
- 1.2.3 Growth areas for drug delivery
- 1.3 Product pipeline
- 1.3.1 Key cancer subtypes
- 1.3.2 Drug delivery improving probability
- 2 Market drivers and opportunities for drug delivery technologies
- 3 Key drug delivery companies and academic researchers in cancer research
- 4 Current drug delivery issues and opportunities in chemotherapy
- 4.1 Active targeting
- 4.2 Passive targeting
- 4.3 Orally active targeting
- 5 Active targeted drug delivery platforms
- 5.1 Tumor-specific antigens and receptors as carriers
- 5.1.1 Case Study: Avidimer Nanoparticles/ATI-001 (Avidimer Therapeutics)
- 5.1.2 Case Study: IL13-PE38 (NeoPharm/Nippon Kayaku)
- 5.2 Peptide-based drug delivery
- 5.2.1 Case Study: Vectocell Technology/DTS-108 (Diatos)
- 5.2.2 Case Study: TSP Technology/DTS-201 (Diatos)
- 5.3 Antibody-based drug delivery
- 5.3.1 Case Study: radio-imunotherapy/IMMU-107 (Immunomedics/UCB)
- 5.3.2 Case Study: antibody drug conjugates/SGN-35 & SGN-75 (Seattle Genetics)
- 5.3.3 Case Study: tumor-activated prodrug (TAP)/HuN901-DM (ImmunoGen) and Trastuzumanb-MCC-DM1 (ImmunoGen/Genentech)
- 5.4 Second-generation antibody fragments for drug delivery
- 5.4.1 Case Study: single-chain antibodies (SCAs) (Enzon)
- 5.4.2 Case Study: SS1(dsFv) PE38 (NeoPharm)
- 5.5 ADEPT
- 5.5.1 Case Study: ADEPT platform/ZD2767P (academic institutions)
- 5.6 Nucleic acid-based drug delivery
- 5.6.1 Case Study: Aptamer-conjugated nanoparticles (Harvard Medical School/MIT)
- 5.5 Our Opinion on Active Targeting Technologies
- 6 Passive targeted platforms
- 6.1.1 Case Study: Nanoparticle albumin bound formulation/Abraxane (Abraxis BioSciences/AstraZeneca)
- 6.2 Liposomal encapsulation
- 6.2.1 Case Study: NeoLipid technology/LE-SN38 (NeoPharm)
- 6.2.2 Case Study: STEALTH liposome technology/Doxil (ALZA)
- 6.2.3 Case Study: sphingosome technology (INEX/Hana Biosciences)
- 6.3 Synthetic polymers
- 6.3.1 Case Study: Platinate polymers/ProLindac (Access Pharmaceuticals)
- 6.3.2 Case Study: Polyglutamate drug delivery/Xyotax (Cell Therapeutics)
- 6.4 Pegylation
- 6.4.1 Case Study: Customized Linker TechnologyTM/PEG-SN38 (Enzon)
- 6.5 Second-generation smart bioerodible polymer systems
- 6.5.1 Case Study: ReGel® polymer technology/DTS-301 (Protherics/Diatos)
- 6.6.1 Case Study: Bioerodible polymers/Locteron (OctoPlus/Biolex)
- 6.6 Our opinion on passive targeting technologies
- 7 Oral Targeted Drug Delivery Platforms
- 7.1.1 Case Study: eligen technology/oral gallium (Emisphere Technologies/Genta)
- 7.1.2 Case Study: Contramid (Labopharm)
- 7.1.3 Case Study: Polymeric Nano-Delivery System (Labopharm/ Debiopharm)
- 7.1.4 Case Study: BiotransportTM Nanomedicine/SP1049C (Supratek)
- 7.1.5 Case Study: Lipid Polymer Micelle (LPM™) system/LPM Leuprolide (DOR BioPharma)
- 7.1.6 Case Study: Cobalamin™-mediated drug delivery (Access Pharmaceuticals)
- 7.2 Our opinion on oral drug delivery technologies in cancer
- 8. Market trends in drug delivery in cancer
- 8.1 Key drug delivery players in the oncology arena
- 8.2 Recent partnerships and acquisitions
- 8.2.1. Specialist technology and cross-platform providers
- 8.2.2. Emerging specialty pharma companies
- 8.2.3. Spin-off companie
- 8.2.4. Pharma acquisitions
- 8.3 Market trends now 2006-2012
- 8.3.1 Historical drug delivery market 2000-2005
- 8.3.2 Global drug delivery market 2006-2012
- 8.3.3 Global advanced cancer drug delivery market 2006-2012
- 8.3.4 Pharma drivers and drug delivery trends by 2012
- 8.4 Market by 2020
- 8.4.1 Global advanced drug delivery market by 2020
- 8.4.2 Global advanced cancer drug delivery by 2020
- 8.4.3 Pharma drivers and drug delivery trends by 2020
- 8.3.5 Drug delivery trends by 2020
- 9 Summary & Conclusions
- 10 Bibliography
- 11 Acknowledgements
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
